Flow cytometry analysis of the collected tumours showed that this combo treatment greatly increased the recruitment of macrophages (CD45+F4/80+), in particular of the M1 phenotype, as compared with the IR700@Nb289‐OMVs plus NIR or the CD47 nanobody alone although both of treatments alone have also resulted in increased recruitment of macrophages and the M1 phenotype (Figure 6N), indicating that the CD47 blockade combo treatment can promote the greatest innate immune activation. The gene discussed is PTPRC; the disease is neoplasm.